Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients
about
CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.InCoB2014: mining biological data from genomics for transforming industry and health.Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.
P2860
Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Novel SNP improves differentia ...... mall cell lung cancer patients
@ast
Novel SNP improves differentia ...... mall cell lung cancer patients
@en
Novel SNP improves differentia ...... mall cell lung cancer patients
@nl
type
label
Novel SNP improves differentia ...... mall cell lung cancer patients
@ast
Novel SNP improves differentia ...... mall cell lung cancer patients
@en
Novel SNP improves differentia ...... mall cell lung cancer patients
@nl
prefLabel
Novel SNP improves differentia ...... mall cell lung cancer patients
@ast
Novel SNP improves differentia ...... mall cell lung cancer patients
@en
Novel SNP improves differentia ...... mall cell lung cancer patients
@nl
P2093
P2860
P1433
P1476
Novel SNP improves differentia ...... mall cell lung cancer patients
@en
P2093
Frank Eisenhaber
Joo Chuan Tong
Mengling Feng
Natalia Liem
Ross A Soo
Sharmila Adhikari
Srinath Sridharan
Tzia Liang Mah
Vachiranee Limviphuvadh
P2860
P356
10.1186/1471-2164-15-S9-S20
P407
P478
15 Suppl 9
P577
2014-12-08T00:00:00Z